Hoffmann Boris A, Kuck Karl-Heinz, Andresen Dietrich, Spitzer Stefan G, Hoffmann Ellen, Schumacher Burghard, Eckardt Lars, Brachmann Johannes, Becker Rüdiger, Steven Daniel, Rostock Thomas, Jünger Claus, Senges Jochen, Willems Stephan
University Heart Center, Department of Cardiology-Electrophysiology.
J Cardiovasc Electrophysiol. 2014 Mar;25(3):242-9. doi: 10.1111/jce.12319. Epub 2013 Dec 9.
Catheter ablation (CA) has emerged as a widespread therapeutic option in the treatment of atrial fibrillation (AF). Currently, no safety data with regard to the impact of the underlying structural heart diseases (SHD) are available. We sought to assess the risk for acute and long-term complications during CA of AF in relation to underlying SHD.
We included 6,211 patients in a prospective registry undergoing CA of AF in 41 nationwide centers. All patients were divided into 4 groups according to the underlying heart disease: No SHD (69.4%), hypertensive heart disease (HHD) (12.0%), coronary artery disease (CAD) (15.1%), and cardiomyopathy (CM) (3.6%). In univariate analysis, patients with HHD had an overall complication rate of 7.28%, whereas patients without an SHD had a significantly lower rate of 6.01% (P < 0.01). Multivariate analysis revealed that HHD (adjusted odds ratio [OR]: 1.97 [95% confidence interval (CI): 1.02-3.83], P = 0.0442) and age (years; OR: 1.04 [95% CI: 1.01-1.07], P = 0.0155) were independent predictors of severe, nonfatal complications and death. Other SHD including CAD (OR: 1.48 (0.73-3.00), P = 0.2797) and CM (OR: 2.37 [0.70-7.99], P = 0.1630) failed to reach statistical significance. Male sex was protective (OR: 0.47 [95% CI: 0.27-0.81], P = 0.0062).
In general, CA of AF has a low number of severe complications. In our prospective registry HHD emerged as an independent predictor of severe, nonfatal complications during AF ablation but other SHD including CAD and CM did not. The influence of HHD on the complication rate should be considered in patient selection.
导管消融术(CA)已成为治疗心房颤动(AF)的一种广泛应用的治疗选择。目前,关于潜在结构性心脏病(SHD)影响的安全性数据尚不可得。我们试图评估与潜在SHD相关的AF导管消融术中急性和长期并发症的风险。
我们纳入了在全国41个中心接受AF导管消融术的6211例患者的前瞻性登记研究。所有患者根据潜在心脏病分为4组:无SHD(69.4%)、高血压性心脏病(HHD)(12.0%)、冠状动脉疾病(CAD)(15.1%)和心肌病(CM)(3.6%)。单因素分析显示,HHD患者的总体并发症发生率为7.28%,而无SHD患者的发生率显著较低,为6.01%(P<0.01)。多因素分析显示,HHD(调整后的优势比[OR]:1.97[95%置信区间(CI):1.02 - 3.83],P = 0.0442)和年龄(岁;OR:1.04[95%CI:1.01 - 1.07],P = 0.0155)是严重非致命并发症和死亡的独立预测因素。其他SHD包括CAD(OR:1.48(0.73 - 3.00),P = 0.2797)和CM(OR:2.37[0.70 - 7.99],P = 0.1630)未达到统计学显著性。男性具有保护作用(OR:0.47[95%CI:0.27 - 0.81],P = 0.0062)。
总体而言,AF导管消融术的严重并发症数量较少。在我们的前瞻性登记研究中,HHD是AF消融术中严重非致命并发症的独立预测因素,但其他SHD包括CAD和CM并非如此。在患者选择时应考虑HHD对并发症发生率的影响。